Joshua Michael Bauml

基本信息

浏览量：24

职业迁徙

个人简介

Dr. Joshua Bauml is a medical oncologist in Philadelphia, Pennsylvania and is affiliated with multiple hospitals in the area, including Hospitals of the University of Pennsylvania-Penn Presbyterian and Philadelphia Veterans Affairs Medical Center.

研究兴趣

论文共 238 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Amivantamab Plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Byoung C. Cho,Shun Lu,Enriqueta Felip,Alexander I. Spira,Nicolas Girard,Jong-Seok Lee,Se-Hoon Lee,Yurii Ostapenko,Pongwut Danchaivijitr,Baogang Liu,Adlinda Alip,Ernesto Korbenfeld,Josiane Mourao Dias,Benjamin Besse,Ki-Hyeong Lee,Hailin Xiong,Soon-Hin How,Ying Cheng,Gee-Chen Chang,Hiroshige Yoshioka,James C. -H. Yang,Michael Thomas,Danny Nguyen,Sai-Hong I. Ou, Sanjay Mukhedkar,Kumar Prabhash,Manolo D'Arcangelo,Jorge Alatorre-Alexander, Juan C. Vazquez Limon, Sara Alves,Daniil Stroyakovskiy, Marina Peregudova,Mehmet A. N. Sendur,Ozan Yazici,Raffaele Califano, Vanesa Gutierrez Calderon,Filippo de Marinis,Antonio Passaro,Sang-We Kim,Shirish M. Gadgeel,John Xie,Tao Sun,Melissa Martinez, Mariah Ennis, Elizabeth Fennema,Mahesh Daksh,Dawn Millington, Isabelle Leconte,Ryota Iwasawa,Patricia Lorenzini,Mahadi Baig, Sujay Shah,Joshua M. Bauml,S. Martin Shreeve, Seema Sethi,Roland E. Knoblauch,Hidetoshi Hayashi

The New England journal of medicineno. 6 (2025): 620-621

引用21浏览0WOS引用

Preventing Infusion-Related Reactions with Intravenous Amivantamab: Primary Results from SKIPPirr, a Phase 2 Study

G. Lopes,A. I. Spira,J. -Y. Han,J. -Y. Shih, C. Mascaux, U. Basu Roy,J. Zugazagoitia,Y. J. Kim,C. -H. Chiu, S. -W. Kim,E. Nadal,I. Gil-Bazo, S. Murphy,P. Mahadevia, B. G. Anderson,K. Xia, G. Wang,J. M. Bauml,M. Chioda, J. Simoes, L. Paz-Ares

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S104-S105

引用0浏览0引用

Subcutaneous Versus Intravenous Amivantamab, Both in Combination with Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results from the Phase III PALOMA-3 Study

JOURNAL OF CLINICAL ONCOLOGYno. 30 (2024)

引用0浏览0WOS引用

1269P Preventing Infusion-Related Reactions with Intravenous Amivantamab: Updated Results from SKIPPirr, a Phase II Study

L.G. Paz-Ares,A.I. Spira,J-Y. Han,J-Y. Shih, C. Mascaux, U. Basu Roy,J. Zugazagoitia, Y.J. Kim,C.H. Chiu,S-W. Kim,E. Nadal,I. Gil Bazo,P. Mahadevia, B. Anderson,K. Xia, G. Wang,J.M. Bauml,M. Chioda, J. Simões,G. Lopes

Annals of Oncology (2024): S812

引用0浏览0引用

LBA55 Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Versus Osimertinib in Patients with EGFR-mutant Advanced Non-Small Cell Lung Cancer: an Early Analysis from the Phase III MARIPOSA Study

B. Besse,S-H. Lee,S. Lu,D. Stroyakovskiy,O. Yazici,J.R. Rodriguez Cid, H. Hayashi,D. Nguyen,J.C-H. Yang,M. Gottfried, A.C. Gelatti,S. Owen,S-H.I. Ou, M. Ennis, S. Sethi,J.M. Bauml, J. Zhang,J.C. Curtin,B.C. Cho

Annals of Oncology (2024): S1245-S1246

引用0浏览0引用

OA06.04 Phase II Study of Pembrolizumab and Itacitinib for Patients with Metastatic NSCLC Expressing PD-L1: Long-Term Follow Up

M.E. Marmarelis, D.J. Cantor,D. Mathew, T. McWilliams,J. Bauml,W.-T. Hwang, A. Singh,C. D'Avella, C. Davis, D. Ye, L. Sun,C. Ciunci,C. Aggarwal,R.B. Cohen, A. Minn, J. Wherry,C.J. Langer

Journal of Thoracic Oncologyno. 10 (2024): S20

引用0浏览0引用

Amivantamab Plus Lazertinib Vs Osimertinib in Firstline EGFR-mutant Advanced NSCLC: Longer Follow-up of the MARIPOSA Study

S. Gadgeel,B. C. Cho,S. Lu,E. Felip,H. Hayashi,A. I. Spira,B. Besse, M. Thomas,S. Owen,Y. J. Kim,S. -H. Lee,J. Mourao Dias,Y. -G. Lee, Y. Zhao, Y. Fang,N. Girard, Z. Liu,P. Sun, S. C. Sousa Oliveira, H. Shen,L. Paz-Ares, S. Matsumoto, H. Tanaka, A. R. Ahmad, T. Andabekov,P. Sunpaweravong, O. Ozyilkan,J. C. -H. Yang,M. Gottfried, O. Hernandez,M. Kimmich,D. Cortinovis, D. L. Kaen, L. V. Garcia Montes,S. Popat, T. Newsom-Davis,J. Xie,T. Sun,E. Fennema, M. Daksh, M. Ennis, S. Sethi,J. M. Bauml,D. Nguyen

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S10-S11

引用0浏览0引用

Enhanced Vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study

B. C. Cho,N. Girard, M. B. Sauder, J. Feldman, W. Li,F. Bozorgmehr,M. Mak, J. Smith, J. Simoes,P. Mahadevia, B. G. Anderson, T. Romero,K. Xia, G. Wang, S. Murphy,J. M. Bauml,A. I. Spira

JOURNAL OF THORACIC ONCOLOGYno. 10 (2024): S347-S347

引用0浏览0引用

Amivantamab Plus Chemotherapy with and Without Lazertinib in EGFR-mutant Advanced NSCLC after Disease Progression on Osimertinib: Primary Results from the Phase III MARIPOSA-2 Study

A. Passaro,J. Wang, Y. Wang,S. -H. Lee,B. Melosky,J. -Y. Shih,K. Azuma,O. Juan-Vidal,M. Cobo,E. Felip,N. Girard,A. B. Cortot,R. Califano,F. Cappuzzo,S. Owen,S. Popat,J. -l. Tan, J. Salinas,P. Tomasini,R. D. Gentzler,W. N. William,K. L. Reckamp, T. Takahashi, S. Ganguly,D. M. Kowalski,A. Bearz,M. MacKean, P. Barala,A. B. Bourla, A. Girvin, J. Greger,D. Millington, M. Withelder,J. Xie,T. Sun, S. Shah,B. Diorio,R. E. Knoblauch,J. M. Bauml, R. G. Campelo,B. C. Cho

ANNALS OF ONCOLOGYno. 1 (2024)

引用93浏览0WOS引用

3MO Amivantamab Plus Chemotherapy Vs Chemotherapy in EGFR-mutant Advanced NSCLC after Progression on Osimertinib: A Post-Progression Analysis of MARIPOSA-2

R.D. Gentzler,A. Spira,B. Melosky,S. Owen, T. Burns,E. Massarelli, M. Nagasaka, B. Fang,R.E. Sanborn,O.G. Arrieta Rodriguez, C. Card,F. Cappuzzo,K. Xia, P-L. Chu, S. Shah,B. Diorio, A. Garvin,P. Mahadevia,J.M. Bauml,K. Reckamp

ESMO Open (2024): 102582

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn

Executive Medical Director

论文共 238 篇作者统计合作学者相似作者